financetom
Business
financetom
/
Business
/
Nayax Expands In Brazil With UPPay Acquisition, Taps Into New Payment Points
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nayax Expands In Brazil With UPPay Acquisition, Taps Into New Payment Points
Feb 28, 2025 7:57 AM

Nayax Ltd ( NYAX ). , a global commerce enablement and payments platform, has acquired UPPay, a digital payment and telemetry provider for automated self-service coffee machines in Brazil.

The purchase price, equating to an enterprise value of R$32.75 million (~$5.3 million), will be paid with cash on hand and includes the earnout amount of up to ~$0.47 million.

Nayax ( NYAX ) entered the Brazilian market in 2024 when it acquired VMtecnologia, a technology provider for the automated self-service industry in Brazil. With the acquisition of UPPay, Nayax ( NYAX ) and VMtecnologia will serve more than 25,000 new unattended points of sale in Brazil.

UPPay will integrate operationally with VMtecnologia, consolidating both companies’ sales, distributional, and technical expertise.

This strategic acquisition strengthens Nayax’s foothold in the Brazilian market and broadens its reach across Latin America, offering merchants a comprehensive suite of affordable payment solutions.

“UPPay’s sophisticated yet affordable platform complements our vision of empowering retailers of all sizes with real-time operational insights, streamlined payments, and seamless customer experiences,” stated Yair Nechmad, CEO and Chairman of Nayax ( NYAX ).

As of September 30, 2024, the company had $89 million in cash and cash equivalents and short-term deposits. 

Nayax ( NYAX ) will release its fourth quarter and 2024 earnings on March 4, 2025.

Price Action: NYAX shares traded lower by 1.12% at $37.24 at last check Friday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nuvalent Insider Sold Shares Worth $1,654,311, According to a Recent SEC Filing
Nuvalent Insider Sold Shares Worth $1,654,311, According to a Recent SEC Filing
Apr 1, 2024
08:28 AM EDT, 04/01/2024 (MT Newswires) -- Deborah Ann Miller, Chief Legal Officer, on March 28, 2024, sold 22,000 shares in Nuvalent ( NUVL ) for $1,654,311. Following the Form 4 filing with the SEC, Miller has control over a total of 33,300 shares of the company, with 33,300 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1861560/000095017024038721/xslF345X03/ownership.xml ...
Why Clothing Company Guess? Shares Are Surging Today
Why Clothing Company Guess? Shares Are Surging Today
Apr 1, 2024
Guess? Inc ( GES ) shares are trading higher in the premarket session on Monday. The company’s Board of Directors has authorized a new share repurchase program of up to $200 million of the common stock. As of February 3, 2024, the company had no remaining authority to purchase its common stock under the 2021 Share Repurchase Program. As part of this...
Mexico's Grupo Coppel to invest over $700 million in 2024 to boost store network
Mexico's Grupo Coppel to invest over $700 million in 2024 to boost store network
Apr 1, 2024
MEXICO CITY (Reuters) - Mexican retailer and lender Grupo Coppel plans to invest more than 12 billion Mexican pesos ($726 million) this year to boost its store network and reduce its environmental footprint, it said in a statement on Monday. The company, owned by the billionaire Coppel family, said it would remodel some of its stores and open more than...
Antibe Therapeutics Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
Antibe Therapeutics Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
Apr 1, 2024
08:26 AM EDT, 04/01/2024 (MT Newswires) -- Antibe Therapeutics Inc. ( ATBPF ) , which gained more than 4.5% last Thursday, on Monday announced that it received verbal notice from the U.S. Food and Drug Administration on March 28 that otenaproxesul has been placed on clinical hold, postponing the initiation of the planned Phase II trial. Antibe expects to receive...
Copyright 2023-2026 - www.financetom.com All Rights Reserved